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Class II Molecules of the Major Histocompatibility Complex

ABSTRACT:
Within the study of genetic polymorphism, species diversity, and natural
selection, a common factor continually takes the lead in the global demand for the
attention of geneticists and other scientists, as well as medical doctors. This common
factor is the major histocompatibility complex, or the MHC. In this thesis I address the
relevance of the MHC to the common layman as well-for the highly studied, multitalented MHC has also been shown to influence attraction between members of the
opposite sex. In order to describe how the MHC affects everyday life, I will first describe
exactly what it is, how it works, and the processes that occur when the MHC does not
function properly.
The major histocompatibility complex is a vital component of the immune
system. It is a genetic complex located on the short arm of chromosome 6. Two protein
strands comprise the MHC, corresponding to two different classes of MHC genes, class I
and class II. Class II molecules are the focus of my paper and presentation. Class II
genes are composed of the human leukocyte antigens (HLA-) -DP, -DQ, and -DR. Each
class II gene has two strands, and each strand has two domains. Similarly, Class I has
two strands, and mUltiple domains. The class I and class II genes encode for proteins
which aid in distinguishing "self" particles from "non-self" particles within the body.
Class I molecules are present on all "self" cells, widely distributed throughout the body,
and class II molecules are present on antigen-presenting cells of the immune system.
These cells, when complexed with MHC class II serve to label "non-self" particles for
destruction by the immune system.
When the MHC is mutated, absent, or otherwise altered, multiple and complex
problems may result, from the so-called "bare lymphocyte syndrome," where MHC II
molecules may be completely absent (resulting in a general immune deficiency), to
generation of autoimmune diseases such as lupus and various forms of arthritis.
Population-based control studies have been performed which indicate the involvement of
the MHC as a cause in many such polygenic autoimmune diseases. On a lighter note, studies with a focus on natural selection have also been performed which propose the
MHC as a factor in determining attraction to members of the opposite sex in humans.
In summation, the MHC is an integral factor in determining immune health,
predisposition to autoimmune disease and susceptibility to various treatments; it also
affects aspects of everyday life such as whom you flirt with next. Current research is
uncovering more every day about this portion of the genome which appears to have great
power and influence in such diverse instances.
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Scientists have historically searched for a biological basis for the differences
observed among members of the human race. What is it truly that sets each person apart?
How could it be that every human responds to the environment, with its numerous
pathogens, in a distinctly different way? Often groups of people with similar
backgrounds or genetic histories may respond to a certain pathogen drastically
differently-or not at all-than another population of people whom the same pathogen
decimates.
The answer to this complex is a complex within itself-the major
histocompatibility complex, or MHC. The MHC is an integral component of the immune
defense system. Antigen presentation to T cells, as well as T cell development and
activation, is highly regulated by genes of the MHC. Two major types of molecules
compose the MHC: class I and class II. Class I molecules are present on all nucleated
cells throughout the body. These are the molecules used to communicate "self' peptides
to the immune system. Class II molecules, on the other hand, the focus of this paper, are
usually limited to expression upon antigen-presenting cells such as macrophages,
monocytes, dendritic cells, and B cells, as well as thymic epithelium. Cells which are not
antigen-presenting cells may be subjected to the cytokine interferon gamma (IFN-y) and
thus induced to express class II molecules of the MHC (Dorak 2003, Mastemak et al.
2000).
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The MHC molecules were identified because of their significance in organ
transplantation rejection and correlation to many autoimmune diseases. A transplanted
organ may be rejected if the MHC proteins of the two individuals differs by a single
amino acid sequence. In 1951, geneticist George D. Snell of the Jackson Laboratory in
Bar Harbor, Maine, instigated investigation into the major histocompatibility complex
with his publication of two papers (Klein 2001).
At that time, only the histocompatibility complex of a laboratory mouse had been
identified. It was referred to as the H2 system, for the name major histocompatibility
complex did not enter the field until the 1970s, when more knowledge of the subject was
unearthed, and it emerged that many vertebrates possessed genetic complexes that were a
great deal similar to the H2 system of the laboratory mouse. Research on the MHC has
progressed exponentially from its beginning in 1951, when only two scientists were
actively involved-Snell and another by the name of Peter A. Gorer in London. Few
others were even researching MHC-relevant issues (Klein 2001).
Rose O. Payne, a hematology department technician at the Stanford University
School of Medicine, had just begun a foray into the question of whether thrombopenias
and leukopenias had an immunological basis. She soon discovered that what she had
thought were self antibodies had actually been induced by foreign white blood cells from
blood transfusion donors. Later Payne, in collaboration with Walter Bodmer, using an
improved antibody source, identified the antigens referred to as LA; this antigen set
eventually became the LA portion of the human MHC human histocompatibility
leukocyte antigen identity (HLA) (Klein 2001).
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During these advancements, Gorer and Snell continued their research in the
pursuit of the MHC. They were specifically concerned with the role of circulatory
antibodies in their research. Hypothesizing that there might be a connection between
allogenic transplant rejection factors and antigens of the blood, Gorer's reasoning was
that response to transferred foreign blood was similar to the rejection response of grafted
tissue (Klein 2001). Snell, on the other hand, left the mechanism study to Gorer and
instead focused on the loci makeup involved in such tissue rejection. The location and
characteristics of the histocompatibility loci became Snell's focus; he soon realized that
he needed a way to differentiate among the loci. Through the production of coisogenic
mouse strain pairs, which had many problems with the experiment itself, Snell was
eventually able to determine important differences in the characteristics of the multiple H
loci. Snell also discovered a "marker gene" for a specifically influential H locus, which
greatly aided in his research (Klein 2001).
Thus Snell was another historical proponent of the MHC identity. Differing
between "major" and "minor" H loci, and discovering that the H2 locus was most
significant and hence the "major;" led to use of "major" as the first word of MHC.
Snell's later research illustrated the complexity of the genetics of the H2 locus, in tum
initiating addition of the word "complex" in MHC (Klein 2001).
After discovery of the polymorphism, complexity, and high influence on
transplant rejection which the MHC possesses, its popularity soared. Scientists
everywhere got involved, from clinicians who discovered links from diseases to specific
HLA alleles, to frustrated transplant surgeons, to immunologists who came to realize how
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important the MHC was in the role of adaptive immunity, to geneticists intrigued by the
notion of genetic analysis experiments in human systems (Klein 2001).
Every MHC class II molecule is composed of two chains-an a and a ~, which
are combined as a heterodimer. The a chain is slightly larger, about 3kDa more, than the
~

chain due to glycosylation characteristics. There are also two a domains (a1 and (2)

and two

~

domains

(~1

and

~2)

that comprise each of the a and ~ chains of these

molecules. The binding site formed by the configuration of these domains is the basis for
the extensive polymorphism of these molecules. The

~

domain forms eight anti parallel

fragments, which combine to become a foundation for the a domain formation of two
antiparallelloops; with a disulfide bond for attachment of the domains, one solitary
peptide binding site is the end product. However, this binding site has the ability to
attach to many different peptides-so-called "high affinity and low specificity" perhaps
due in part to the hydrogen bonds responsible for maintaining attachment of the peptide
to the side chains lining the class II molecule. Binding of the class II classical molecules
to the peptides is moderated greatly by the invariant nonclassical molecules of HLA-DM
and HLA-DO (Ting and Trowsdale 2002).
The MHC Class II complex may be found upon dendritic cells, which are among
the most important APCs due to their high effectiveness. In circulation, a dendritic cell
greatly resembles an irregularly nucleated lymphocyte containing many mitochondria.
Dendritic cells are often found attached to fibroblastic reticular cell conduits (FRCCs),
which are fiber-filled tubes in which the manufacturing of cytokines and related products
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occurs. FRCCs are effective messengers and pathways for migrating cells. The site
formed when dendritic cells attach to FRCCS encourages antigen presentation to
migrating lymphocytes. These lymphocytes are continuously traveling from the lymph to
the blood and back again. In the blood, lymphocytes are found to be spherical in shape,
with many surface microvilli. Lymphocytes may be found at rest; once they have been
instigated to emigrate throughout the body, a polarization process begins to aid the
lymphocyte on its way. Chemokines signal a lymphocyte to polarize its organelles as
well as its cytoskeleton. Actin becomes concentrated in the anterior lamellipodium, and
tubulin bundles becomes concentrated in the posterior uropod. Intermediate filaments of
vimentin then quickly collapse, plectin is expressed, and becomes involved with lamin B,
actin, and vimentin in the lymphocyte, resulting in full polarization and thus activation of
the lymphocyte (Madigan et al. 2000; Clausen et al. 1998).
Other cells upon which antigens may be presented include macrophages,
monocytes, and B cells. Monocytes differentiate to become macrophages, which aid in
the specific immune response as well as the destruction of most pathogens they
encounter. Macrophages are found primarily in the spleen and lymphoid tissue, whereas
the precursor monocyte is found circulating throughout the blood and lymph. Once
phagocytosis by an APC such as a macrophage has taken place, that cell becomes primed
to phagocytize much more efficiently (Madigan et al. 2000).
B cells are not only important in antigen presentation, but they are also critical
antibody factories and instigators of the memory function of the immune system.
Immunoglobulin molecules found on the surface of B cells separates them from other
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immune cells. These immunoglobulins are the key to antigen recognition; once exposed
to an antigen, B cells may proliferate to become long-lasting memory cells, which readily
reproduce at the first sign of reexposure to the same antigen. B cells are normally found
in large numbers in lymph node cortexes; this location is crucial for interaction with
antigens (Madigan et al. 2000).
Antigen presenting cells process and deliver their antigen package to T
lymphocytes. Each T cell possesses a T cell receptor (TCR) that is highly specific to a
particular antigen. The two major types of T cells are classified by their cell surface
proteins (either CD4 or CDS). T helper cells, composed of Thl and Th2 groups, possess
the CD4 protein. This set of T helper cells is the primary group of T cells that interacts
with class II molecules. CDS T helper cells, conversely, are associated with the MHC
class I gene complex (Madigan et al. 2000).
Three general isotypes of class II molecules exist in humans, referred to as the
human histocompatibility leukocyte antigens (HLAs): HLA-DP, HLA-DQ, and HLADR. These human leukocyte antigens are found on the short arm of chromosome 6
(6p21.31) (Dorak 2002). Class II molecules of the MHC are responsible for commencing
. the humoral immunity via the coding of heterodimeric glycoproteins. These
glycoproteins are then responsible for the presentation of foreign antigens to the
aforementioned CD4 T cells. Class II molecules also fill a directoral role in developing
as well as activating these T cells, and they are crucial to gene transcription regulation.
This control of the immune response system is a result of a critical regulation of class II
molecular expression. The genetic factors associated with activating the MHC are class
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II transactivator (CIITA) and regulatory factor X (RFX). Both are crucial transactivators
of genes, and both factors may be subject to a "genetic complementation cloning" method
for effective isolation (Boss et al. 2002).
The class II transactivator is a non-DNA binding control factor of MHC
expression, while regulatory factor X is part of the nuclear complex upon which DNA
binding relies. RFX has three subunits referred to as RFXANK (or -B), RFX5, and
RFXAP. These transcription factors bind the cis-acting sequence, the conserved Xl box,
found in promoters of the MHC class II isotypes (HLA-DQ, -DR, and -DP). CIITA also
is believed to associate with certain constituents of the class II promoters, and through its
acidic activation domain activate transcription. The presence of the class II transactivator
as a "molecular switch" is thus illustrated (Boss et al. 2002).
The promoters of the class II isotypes include the W, Xl, X2, and Y boxes.
Regulation is coordinated through these cis-acting elements, which are located within a
few hundred base pairs upstream from each of the different isotypes of class II molecules.
These promoter factors, as well as the structural genes for MHC class II loci are uniquely
conserved (Ting and Trowsdale 2002). Other class II transcription factors are CREB,
which binds the X2 box motif, and NF4, which binds to the Y box motif (Boss et al.
2002).
The position of the class II transactivator in initiating gene expression is a result
of CIITA's involvement with transcription machinery factors and the enzyme
acetyltransferase. Not only does CIITA express acetyltransferase activity, but it also
causes acetylation of nucleosomes via compelling histone acetyltransferases. CIIT A also
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possesses down-regulation properties, most likely because of its titration of CBP, the
CREB-binding protein, from locations on certain genes; specifically, the promoting and
enhancing regions of such genes (Ting and Trowsdale 2002).
This titration of transcription factors and regulation of MHC class II expression
illustrates two methods by which CIITA may exert its power. CIITA has been
extensively studied as a gene regulator that more than likely influences a great deal of
gene activity (Boss et al. 2002).
Much of the research for MHC class II regulation has been based upon studies
done with humans presenting a genetic deficiency, either in CIITA or RFX complex units
and binding. MHC class II deficiency is often referred to as bare lymphocyte syndrome,
because of the usual absence of class II expression on lymphocytes in the bodies of these
patients. This immunodeficiency is an extremely rare form of an autosomal recessive
genetic disease. Two general forms of the MHC class II deficiency have been
distinguished. One form is a result of CIITA mutation, and the other is a result of defects
in the RFX complex formation or defects in any aspect of subunit binding. These
mutations are labeled as different types depending upon their complementation group
(A1caide-Loridan et al. 2001; Mach et al. 1996).
Complementation group refers to the unaltered phenotype of fusions of paired
cells; genes for these complementation groups encode integral proteins needed for
transcription of MHC II genes. Complementation group A genetic defect has been found
to encode for CIITA; and only recently, geneticists from the Howard Hughes Medical
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Institute in San Francisco have determined that complementation groups B, C, and D are
associated with genetic mutation in RFX subunits RFXANK, RFX5, and RFXAP,
respectively. A little-known controversial complementation group E has been speculated
which encodes a chromatin organizational protein (Jabrane-Ferrat et al. 2000).
The RFX complex, which binds to the MHC class II promoters at the X and S (Y)
boxes, is comprised of the three subunits RFXANK (B), RFXAP, and RFX5. These
proteins differ in size, with RFXANK the smallest at 33 kDa, RFXAP in the middle size
category at 41 kDa, and RFX5 the largest at 75 kDa. A DNA-binding domain is present
upon RFX5, (although it cannot bind DNA even in a long fragment by itself) and RFXAP
has been shown to bind slightly to RFX5 in vivo (Jabrane-Ferrat et al. 2000; Brown et al.
1997).
The mechanistic formation of this RFX complex has been excessively researched
to no major avail. It has been shown that the RFX complex may be nucleated without the
presence of DNA via the weakly linked interactions in vitro between RFXAP and
RFXANK. Using E. Coli to express the RFXANK binding protein, while performing in
vitro translation of the wild-type proteins of RFXAP and RFX5, it was shown by
researchers at the Howard Hughes Medical Institute that this binding protein could repair
MHC II expression on RFXANK-deficient cells. When the RFXAP and RFX5 were
mixed with this binding protein, there was no binding of RFX5 to the binding protein;
however, there was a significant amount of binding between RFXAP and the binding
protein of RFXANK. To illustrate that this same binding situation occurs in vivo,
plasmid-transfected cells were subjected to expression of these proteins; the plasmids
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used were predetermined RFXANK protein regulators, HA-Iabeled RFXAP protein, or a
mixture of the two. Western blot using antibody to HA was performed to detect RFXAP;
cells transfected with a plasmid of either RFXANK protein regulator or HA-Iabeled
RFXAP protein expressed no RFXAP. However, if a transfected cell possessed a
plasmid containing both, then the anti-HA antibody was expressed to a high degree along
with RFXAP (Jabrane-Ferrat et al. 2000).
Using a dual hybrid mammalian system, experiments have further illustrated that
there is no observed fusion between RFX5 and RFXANK and a very small amount is
observed between RFXAP and RFX5; however, it has also been suggested that perhaps
RFX5 binds to a combined form of RFXANK and RFXAP. Another opinion suggests
that perhaps RFXAP is a connector for the three by joining both RFXANK and RFX5
(Jabrane-Ferrat et al. 2000).
When the RFXAP and RFXANK proteins become mutated, the assembly of the
RFX complex cannot be completed, even when DNA is available. When proteins from
RFXAP are mutated, they are C-terminally deficient and as a result cannot bind to
RFXAP. In a similar fashion, RFXANK mutant proteins are not able to bind to RFXAP.
Thus if a mutation occurs in one of these Band D complementation groups, binding to
the other group is hindered entirely; the very beginning of the RFX complex assembly is
aborted. A summary of the RFX complex assembly and resultant DNA binding is
illustrated as follows:
"RFXANK and RFXAP assemble first and represent a scaffold that
attracts RFX5. Upon binding, the conformational change of RFX5 exposes its
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DNA-binding domain, which anchors the RFX complex to X and S boxes. The
final shape of the RFX complex also allows RFXAP to make extensive contacts
with DNA. Another part of the RFX5 protein touches CIITA, which is attracted
to MHC IT promoters by a combinatorial surface formed on [conserved upstream
sequences]." (Jabrane-Ferrat et al. 2000)

Experiments in this aspect of the RFX complex assembly illustrated that the
presence of DNA does not aid or support formation of the RFX complex, especially when
there exists a mutation in the RFX subunits. The subunits cannot independently bind to
DNA or form a proper RFX complex, nor can any double subunit formation. The
correctly and wholly assembled nuclear complex from the wild-type forms of the RFX
subunits must be formed in order for proper DNA binding. Any individual protein
binding of RFXANK, RFXAP, or RFX5 are not associated with DNA binding (JabraneFerrat et al. 2000).
Other studies have attempted to illustrate that it is the ankyrin repeats of the
RFXANK subunit that may be most significant in MHC class IT deficiency. Angela M.
DeSandro, Uman M. Nagarajun, and Jeremy M. Boss of the Emory University School of
Medicine's Department of Microbiology and Immunology performed RFX gene
mutagenesis experiments which analyzed and isolated RFX subunit domains, particularly
those responsible for accurate assembly of the nuclear RFX complex. Yet these
researchers also discovered that these factors alone are not enough for proper expression
of MHC class IT molecules. Promoters of MHC class IT must associate with CITT A to
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ensure proper transcription activation. When mutations in CIITA occur, the class II
promoters have filled Xl, X2, and Y boxes; however, if the mutation occurs in the RFX
binding, the Xl, X2, and Y boxes are empty (Boss et al. 2000).
These researchers (Boss et al.) hypothesized that the RFX complex mutation may
have many different aspects, depending upon mutations within each subunit of the
complex. Experiments were undertaken to identify integral components of each of the
RFX subunits required for the various mechanisms of MHC class II expression. The
gene encoding the RFXANK subunit was extensively analyzed because of its suspected
and potentially influential impact upon the remaining two subunits. RFXANK has a Cterminal region, which consists of three ankyrin repeats; at this point in MHC research,
the precise function of these was not known. The researchers at Emory designed
mutation experiments in which deletions were made in regions of RFXANK. These
mutants were then analyzed in the context of MHC class II expression reinstatement in
vivo. Cell lines to be transfected were obtained from bare lymphocyte syndrome patients
whose cells demonstrated splice site mutation homozygosity, with wild type expression
for genes encoding RFX5, RFXAP, and CIITA. Results of this experiment illustrated
that proper RFXANK utility is much more dependent upon the region C-terminal or Nterminal to the ankyrin repeats than it is dependent upon its amino-terminal portion (Boss
et al. 2000).
The Emory team of researchers then went on to perform further analysis of
mutant RFXANK proteins; both DNA binding characteristics and association with other
subunits was assessed. Using a coupled T7 transcription-reticulocyte translation kit, or
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IVT, the subunits were each synthesized and submitted to coimrnunoprecipitations using
anti-RFX5 antibody. Three deficient mutants of RFXANK were also submitted to this

same test. Mutant RFX-B~l had 39 amino acids deleted from its C-terminus, and mutant
RFX-B82 had 122 amino acids deleted from its N-terminus, while mutant RFX-B83 had
a deletion of sequences slightly N-terminal to the ankyrin repeats. The normal RFXANK
proved to fully associate with the remaining two RFX subunits, which were labeled for
the purposes of the experiment. The three mutants, two with their N-terminal regions
removed (which contains the ankyrin repeat sequence linkages) and the other with a Cterminal deletion that allowed the ankyrin repeats to remain, did not associate very well
with the normal RFXAP and RFX5. As compared to the fully normal RFXANK, which
immunoprecipitated 55% of its received substance, the mutants only associated at 43%,
12%, and 0.8% of input, with the least percentage of association corresponding to the
RFXANK mutant that actually contained the three ankyrin repeats but possessed a
deletion in another region. The higher association represented by the first two mutants
mentioned, which were deficient in the first three ankyrin repeats but maintained a region
with a weaker fourth ankyrin repeat, insinuated that perhaps this region of the subunit
plays a critical role as an association domain (Boss et al. 2000).
Further experimentation using RFX5 attempted to analyze more specific
transactivation functions of the gene. Multiple deletions within the 5' and 3' regions were
enacted, and the resulting mutants were tested for efficiency in transactivation of an
MHC II promoter. Assays involving transfections similar to those the Emory geneticists
used for the RFXANK analysis were performed on these RFX5 mutants. Evidence
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appeared to show that mutagenesis greatly affects the properties of RFX5. With the wildtype RFX5, expression of lILA-DR may be significantly reinstated; however, every
mutant but one showed extremely reduced or no expression restoration. Less than five
percent of normal (wild-type) RFX5 activity was illustrated in the first five mutants, and
only twenty five percent of normal expression was displayed by the sixth mutant. The
most likely reason for the difference was found in the specific type of mutation
constructed. The mutants performing less than five percent of normal were missing their
DNA binding domain and possibly others, contributing to transactivation or interaction
with other subunits (Boss et al. 2000).
These RFX5 mutants were also analyzed for their efficiency of interaction with
RFXAP and RFXANK wild types. RFXAP was translated in vitro and incubated with
recombinant RFXANK, and then each mutant of RFX5 was subjected to this incubated
mixture. After purification, the proteins that had formed complexes were analyzed. The
results proved to be different than for the transactivation experiment discussed just
previously; the majority of the RFX5 mutants illustrated effective interaction with
subunits RFXANK and RFXAP. The amounts of interactions and the relation to each
specific mutant led the researchers to believe that RFX5 contains two essential regions
for RFXANK and RFXAP association. One of these regions is believed to be in the N
terminus, within a 92-amino acid sequence, while the other region exists between the 201
and 410 amino acids. The mutant with a deletion in the region of the N terminus
displayed an extremely reduced amount of interaction as compared to the other mutants
(Boss et al. 2000).
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Geneticists at the University of Geneva Medical School in Switzerland proved
that the majority of the RFXAP gene is not necessary for proper expression of its isotype
HLA-DR; however, a larger portion of the gene is necessary for proper HLA-DQ and DP expression. This experiment illustrated that the domain of RFXAP observed is
specific to each particular isotype, as each isotype required different portions and lengths
of the RFXAP gene. It was also suggested by these geneticists that this difference in
isotype need was based upon the distinctions among the reliance that CIITA had upon
this RFXAP domain (Barras et al. 2001). Genetic complementation assay experiments
with MHC II deficient patients that possessed mutations in the RFXAP gene illustrated
classification of RFXAP mutation into complementation group D. Using the RFXAP
wild-type gene, transfection was successfully performed within these patients' cells. The
result was complete reinstatement of class II expression upon the cells used (Fischer et al.
1997).

Further experimentation involving the RFXAP subunit resulted in key clues about
RFX subunit mechanism. Analysis of RFXAP involved mutating the acidic-, amino acidand glutamine-rich regions that differ greatly from the other RFX proteins. Here the Xl
box seemed to playa role, for it was hypothesized that a base pair association existed
between RFXAP and the Xl box. Three RFXAP mutants were constructed for this
experiment-one altered at the C terminal and two altered at the N terminal. The N
terminal deficient mutants were observed to maintain association levels comparable to
the wild-type gene; whereas the C terminal deficient mutant maintained no association.
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The glutamine region, located on the C terminal part of the protein, was therefore
suggested to be critical for wild-type displayed activity levels (Boss et al. 2000).
Experiments involving the association between the RFX complex and CIITA
were constructed to determine which, if any, subunit of the nuclear RFX complex played
a critical role. Because transactivation of this association and indeed the entire system is
dependent upon CIITA's activating position, the connection between CIITA and the RFX
complex was considered extremely pertinent. There is no direct association between
DNA and the class II transactivator; however, the N terminal region of CIITA consists of
a particularly strong domain for transcription activation. Many research groups have
hypothesized that MHC class II factors associate with CIITA, and thus the gene
expression pathway is triggered, but small amount of evidence has actually proved this
theory. The researchers at Emory wanted to test their theory on specific regions of
RFX5-particularly, the C terminus and proline-rich regions; the experiments performed
indeed suggested that these regions of RFX5 were accountable for instigating system
activation. (Boss et al. 2000). And thus another question was raised-does CIITA
association with RFX5 depend upon these two specific regions-the C terminus and
proline-rich region-of RFX5?
Further analysis of direct CIIT A interaction with synthesized RFX subunits
revealed individual and separate association between CIITA and RFX5. When CIITA
was likewise incubated with RFXANK and RFXAP, no association whatsoever was
observed. When a wild type RFX complex was used in the incubation analysis with
CIITA, predictably, a strong association was observed (Boss et al. 2000).
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Another study done by a slightly different group of researchers in Atlanta
conf1lllled that the majority of patients exhibiting MHC class II deficiency or bare
lymphocyte syndrome possessed mutations in the RFXANK gene. The experiments
performed involved purification and sequencing of the proteins comprising the RFX
complex. The isolated RFXANK sequences were then tested for ability to reinstate MHC
class II expression upon cells derived from bare lymphocyte syndrome patients
experiencing a complementation group D deficiency. Expression upon the cells was
restored; the mutation that was covered by the tested RFXANK was found to include a
deletion at a splice site that produced an irregular protein instead of the ankyrin repeats
often deemed crucial to subunit association (Boss et al. 1999).
The experiment proceeded further to illustrate relation of RFXANK function
necessity for the promoters of MHC II genes; tests were undergone which involved the
role of activating a protein reporter containing W, X, and Y box sequences, as well as a
protein reporter without these sequences. When RFXANK was transfected with the
control reporter (no W, X, and Y box sequences), protein expression was very small;
however, when RFXANK was transfected with the reporter containing the box
sequences, a high level of protein was expressed. These results indicated the ability of
RFXANK to perform via the promoter of MHC II; indicating therefore that RFXANK
may be a gene regulator elsewhere besides the class II MHC genes (Boss et al. 1999).
Other studies confirming the theory that RFXANK mutation causes the majority
of bare lymphocyte syndrome patients have also assessed slightly different facets of the
RFXANK role in nuclear complex formation. Geyer et al. of the Howard Hughes
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Medical Institute isolated and identified four ankyrin repeats from the RFXANK subunit.
U sing as a reference other proteins with known ankyrin repeats, the three-dimensional
structure of RFXANK was determined. With a model of the exposed surfaces, the actual
binding sites to CIITA and RFXAP were observed and recorded. Instead of continuous
amino acid chains as has been previously theorized, it was determined that the RFXANK
ankyrin repeat surfaces contain irregular, discontinuous residues. The f)loops of the fIrst
three repeats, as well as a groove helix, were the association points for fusion with
RFXAP. Multiple residues of the external helices of the opposite side ofRFXANK were
the attachment points for CIITA (Geyer et al. 2001).
In relation to bare lymphocyte syndrome, when the deficiency is due to
RFXANK, the alteration consists of a single point mutation that causes a shift in amino
acid production. This critical alteration occurs upon the third ankyrin repeat (necessary
for RFXAP binding), inside the helix structure. Thus when this mutation occurs, it
prevents crucial association between RFXAP and RFXANK, and therefore prevents
formation of the nuclear RFX complex. In this same report, the researchers experimented
with RFX5IRFXANK interactions, concluding in a similar statement to other reports on
RFX5IRFXANK binding: that is, that the proper RFX complex formation needs RFX5;
however, in order to bind, RFX5 must be presented to the combined RFXANK and
RFXAP surfaces; only then will a proper full complex develop (Geyer et al. 2001).
Though bare lymphocyte syndrome is a major concern and area of focus in MHC
class II research, other immunodefIciencies are linked to MHC class II molecules and
mechanistic pathways. Perhaps the most notorious is HIV infection. Similar to BLS,
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human irrnnunodeficiency virus, the causative agent of acquired irrnnunodeficiency
syndrome (AIDS), results in a combined immunodeficiency involving CD4 T cells. By
infecting and altering T cells, HIV impairs the processing and presentation of antigens to
the irrnnune system In this way HIV has also been discovered to hinder MHC class II
determinant transcription (Kanazawa et al. 2000).
A strong transcriptional transactivator encoded by HIV, referred to as Tat, has
been studied for its role in binding MHC II gene transcription. To determine the
promoter target of Tat, Kanazawa et al. performed cotransfection experiments involving
plasmids encoding HLA-DRA promoter-linked chloroamphenicol acetyltransferase, Tat,
and CIITA. Since it was known that this HLA-DRA promoter was associated with
transcription activation through CIITA, it was subjected to co expression with Tat. The
result was an extremely reduced level of chloroamphenicol acetyltransferase activity as
compared to the control containing HLA-DRA promoter linked without Tat. A mutated
form of Tat subjected to the same coexpression test failed to significantly reduce activity;
also, without CIITA present, Tat also failed to significantly reduce activity (Kanazawa et
al. 2000).
Multiple Sclerosis (MS) is another immune deficiency which has been linked to
chromosome 6 (via genome scans), and then more specifically, MHC class II alleles.
Family-based association studies performed on data from the MS Society of Tasmania
have clearly illustrated the inheritance factor involved with MS; certain patterns of HLA
alleles were discovered among family lines of MS patients. These HLA patterns were
not observed, however, in the control populations (Genethics 2003).
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A review of case studies was perfonned in Mexico by Flores-Dominguez et al. to
analyze the involvement of class II alleles in Takayasu arteritis (TA), an inflammatory
disease of the arteries. Studies performed on populations varying from Asian, Arab,
North American, and Mexican mestizo were compiled and the results indicated patterns
within populations, but not as significantly across populations. Human leukocyte
antigens -A31, -B52, -B39, -B5, and -DR2 were found to be associated with TA in
Asian populations; HLA-A2, -A9, -B35, and -DR7 were found to be associated with
Arab populations, HLA-DR4 was found to be associated with North American
populations, and HLA-B5, -B52, and -DR6 were found to be associated with Mexican
Mestizo populations. It was also speculated in this review that the alleles associated may
instigate disease in these genetically susceptible individuals via presentation of an antigen
not yet discovered (Flores-Dominguez et al. 2002).
The University of California-Los Angeles School of Medicine's Division of
Rheumatology has also linked autoimmune disease to class II alleles. Case-control
studies of human systemic lupus erythematosus (SLE), involving so-called "multiplex
families," have led to the association between SLE and its multiple-factor causes,
including MHC class II alleles, as well as complement mutations and Fc gamma receptor
gene polymorphism. Current research perfonned at this institution involves mapping of
these regions (which are presumably linked) in order for further identification (UCLA
2002).
The MHC has also been significantly linked to leukemia; in mice, spontaneous
leukemia development has been illustrated via injecting newborn, low-incidence strains
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with high-incidence strain leukemic filtrates. Conversely, the same experiment
performed on adult strains of the same mice resulted in no spontaneous leukemia
development. The difference was attributed to the homozygosity of the newborns' H2
types and the inoculate, which resulted in leukemia. Strains of mice with heterozygosity
for their H2 type produced no leukemia when inoculated (Dorak 2003).
Similar experiments with enzootic bovine leucosis, the highest incidence
neoplasia observed in cattle, appear to illustrate the retrovirus associated--the bovine
leukemia virus. Lymphocytosis may result in persistent infections, followed by
lymphosarcoma. In determining susceptibility factors, bovine genetics was assessed, and
the major histocompatibility complex was identified as the critical flaw source in these
infections; specifically, linkage disequilibrium existence with the bovine MHC loci
(Dorak 2003).
Reports have also illustrated that MHC variability may influence mating choices
in mice. The MHC of mice, usually referred to as the H2 locus, is able to be
differentially distinguished by mice and select other highly trained species. Female
mating preference experiments were performed in which both H2 identical and H2
differing males were presented. Twenty-nine out of thirty-nine females selected males
different from them at the H2 locus as their primary mating choice. These results
translate into a ratio of 1 (H2 different) to 0.344 (H2 identical) for mating choice.
Natural population observation by other researchers has supported this evidence by
discovering a homozygote deficiency of 27%; with lack of other influential factors, this
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data indicates that female mating selection for males is greatly influenced by genetic
differences at the H2locus (Hedrick 1992).
Interestingly enough, a similar experiment has been performed on humans with
analogous results. Claus Wedekind, a zoologist from the University of Bern, wanted to
determine if differences at MHC loci were involved in attraction between the sexes. He
provided forty-four men with tee shirts, instructing them to wear the shirt for two
consecutive nights. The men were also instructed to abstain from the use of soap,
deodorants, or any other "perfumed cosmetics" during the time the shirts were worn.
After collecting the shirts, Wedekind then presented them to forty-nine female
volunteers, with instructions to smell and then rank the "odourific attractiveness" of the
shirts. As was discovered in the mice studies, the women in this study rated as most
attractive the smells of the shirts worn by males with a largely differing MHC from their
own. The biological basis theorized was that partnering with a human whose MHC is
greatly different results in offspring with a greater amount of MHC variability-thus
increasing the child's immune defense system and chance for survival (Wholistic
Research Co. 2002).
The only contrast to these conclusive results was the portion of women in the
volunteer group who were taking birth control pills. This group of women actually rated
higher the smells of males having similar MHCs. Due to the pregnancy-imitating effects
of birth control pills upon the female body, it was speculated that attraction to a male of
similar MHC is indicative of the natural desire for aid and benefit of family (similar
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MHC) support when pregnant, also a factor that may enhance survival of the offspring
(Wholistic Research Co. 2002).
Thus the importance and influence of the major histocompatibility complex, as
well as its major molecular pathways, its influence on immune function, and resulting
significance in disease, have been illustrated in an attempt to further educate interested
readers. Though the MHC is a relatively new topic in research, many steps have been
accomplished in recent years to further understand this integral immune component.
More research is needed to fully understand many of the interactions that occur, but new
information is published very often, and technological advances have an enormous
impact on such developments. And the next time you fmd yourself particularly attracted
to someone of the opposite sex, you will understand the biological basis for the attraction,
and perhaps trust your sense of smell more often.
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